Cardiovascular Drugs Market

1
Cardiovascular Drugs Market Trends, Size, Share,
Demands, Overview, Growth, Revenue and Forecast
to 2030
sales_at_delvens.com www.delvens.com
2
Sternal Closure Systems Market Trends Forecast
Till 2030
Cardiovascular Drugs Market, by Drug Class
(Anti-hyperlipidaemic, Anti-hypertensives,
Anti-coagulants, Anti-arrhythmic and Others),
Indication (Hypertension, Hyperlipidaemia,
Coronary Artery Disease, Arrhythmia and Others),
Distribution Channel (Hospital, Pharmacies and
Others) and region (North America, Europe,
Asia-Pacific, Middle East and Africa and South
America).
Request For Free Sample Report
https//www.delvens.com/get-free-sample/cardiovasc
ular-drugs-market
sales_at_delvens.com
www.delvens.com
3
Market Overview
Cardiovascular drugs are medications that are
used to treat various conditions related to the
heart and blood vessels. They are prescribed to
manage heart diseases and other cardiovascular
disorders. Cardiovascular medicines are often
used in combination to treat different aspects of
a cardiovascular disease. There are various types
of cardiovascular drugs such as antihypertensives
that are used to lower blood pressure,
anticoagulants that are used to prevent blood
clots, antihyperlipidemic that are used to lower
cholesterol and triglyceride levels,
antiarrhythmics that are used to regulate
abnormal heart rhythms. Most cardiovascular
drugs are prescribed to treat hypertension and
dyslipidaemia which are majorly responsible for
the formation of atherosclerotic plaque within
blood vessels restricting blood flow to the body
parts resulting in multiple cardiac indications
such as stroke, heart failure, cardiomyopathy,
peripheral artery disease, and venous
thrombosis. Purchase this Report
https//www.delvens.com/checkout/cardiovascular-dr
ugs-market
sales_at_delvens.com
www.delvens.com
4
Market Overview
The cardiovascular drugs market can be segmented
based on drug class into anti-hyperlipidaemic,
anti-hypertensives, anti-coagulants,
anti-arrhythmic and others. Based on indication
the market can be bifurcated into hypertension,
hyperlipidaemia, coronary artery disease,
arrhythmia and others. Based on distribution
channel, the market can be segmented into
hospital, pharmacies and others.  Rising
prevalence of cardiovascular diseases (CVDs)
globally, growing research and development and
investment in efficient drug development and
increasing availability of reimbursement policies
are the factors that are contributing to the
growth of the market during the forecast period.
Moreover, the increasing number of admissions in
hospitals, as well as critical care units owing
to cardiovascular diseases (CVDs) has created
demand for the development of cardiovascular
drugs for treatment.
sales_at_delvens.com
www.delvens.com
5
Key Findings
The Cardiovascular Drugs Market is segmented into
various segments such product, procedure,
material, fixation technique, end user and
region Based on drug class the market can be
segmented into anti-hyperlipidaemic,
anti-hypertensives, anti-coagulants,
anti-arrhythmic and others. Based on indication,
the market can be bifurcated into hypertension,
hyperlipidaemia, coronary artery disease,
arrhythmia and others. On the basis of
distribution channel, the market can be segmented
into hospitals, pharmacies and others.
sales_at_delvens.com
www.delvens.com
6
Key Findings
The hospitals segment dominated the market in
this segment which can be attributed to the high
demand for cardiovascular drugs in the
hospital. The market is also divided into
various regions such as North America, Europe,
Asia-Pacific, South America, and Middle East and
Africa. North America is estimated to account for
the largest market share during the forecast
period. Inquire Before Buying
https//www.delvens.com/Inquire-before-buying/card
iovascular-drugs-market
sales_at_delvens.com
www.delvens.com
7
Competitive Landscape

• Amgen Inc
• Baxter
• Bayer AG
• Boehringer Ingelheim International GmbH
• F. Hoffmann-La Roche Ltd
• Gilead Sciences Inc
• Johnson Johnson
• Lupin
• Merck Co., Inc. (MSD)
• Novartis AG
• Pfizer Inc.

• Sanofi S A
• Bristol-Myers Squibb Company
• AstraZeneca
• Janssen Pharmaceuticals, Inc.
• Daiichi Sankyo
• Portola Pharmaceuticals
• United Therapeutics Corp

sales_at_delvens.com
www.delvens.com
8
Recent Developments

• In May 2022, Amgen revealed positive data from
  the Phase 2 OCEAN(a)-DOSE clinical study,
  evaluating olpasiran (formerly AMG 890) in 281
  adult patients with Lipoprotein(a), or Lp(a),
  levels over 150 nmol/L and evidence of
  atherosclerotic cardiovascular disease (ASCVD).
  Olpasiran is a small interfering RNA designed to
  lower the body's production of apolipoprotein(a),
  a key component of Lp(a) that has been associated
  with an increased risk of cardiovascular
  events. 
• In February 2022, the Food and Drug
  Administration (FDA) expanded its approval of
  empagliflozin (Jardiance) for use in adults with
  heart failure (HF), regardless of ejection
  fraction, to reduce the risk of cardiovascular
  death and HF hospitalization. The medication was
  approved in August 2021 to reduce the risk of
  cardiovascular death and HF hospitalization in
  adults with HF with reduced ejection fraction
  (HFrEF).

sales_at_delvens.com
www.delvens.com
9
Contact Information
About Us Delvens is a strategic advisory and
consulting company headquartered in New Delhi,
India. The company holds expertise in providing
syndicated research reports, customized research
reports and consulting services. Delvens
qualitative and quantitative data is highly
utilized by each level from niche to major
markets, serving more than 1K prominent companies
by assuring to provide the information on
country, regional and global business
environment. We have a database for more than 45
industries in more than 115 major countries
globally. Contact Us 44-20-8638-5055 sales_at_del
vens.com WEBSITE https//delvens.com/
sales_at_delvens.com
www.delvens.com